CAJ | 학술논문

表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)已成为晚期非小细胞肺癌治疗的研究热点.在有EGFR突变的患者中,一线单药EGFR-TKI能显著延长患者无进展生存期;EGFR突变是EGFR-TKI治疗获益的有效预测指标.虽然EGFR-TKI与化疗同步联合未能显示出生存优势,但在序贯联合的研究中能延长无进展生存期.EGFR-TKI维持治疗能显著延长无进展生存期.EGFR-TKI二线治疗较安慰剂有显著生存获益,与标准二线治疗总生存期相似,但安全性更好.
표피생장인자수체락안산격매억제제(EGFR-TKI)이성위만기비소세포폐암치료적연구열점.재유EGFR돌변적환자중,일선단약EGFR-TKI능현저연장환자무진전생존기;EGFR돌변시EGFR-TKI치료획익적유효예측지표.수연EGFR-TKI여화료동보연합미능현시출생존우세,단재서관연합적연구중능연장무진전생존기.EGFR-TKI유지치료능현저연장무진전생존기.EGFR-TKI이선치료교안위제유현저생존획익,여표준이선치료총생존기상사,단안전성경호.
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been the focus of clinical trials for treatment of advanced non-small cell lung cancer. In patients with EGFR mutation, first-line EGFR-TKI monotherapy can significantly improve progression-free survival. EGFR mutation is an effective predictor of benefit treatment. Although the use of EGFR-TKI in combination with chemotherapy fails to show a survival advantage,progression-free survival can be prolonged in the sequential study. EGFR-TKI maintenance treatment can significantly prolong progression-free survival. Second-line treatment of EGFR-TKI shows significant survival benefit compared with placebo, has similar overall survival with the standard second-line treatment, but better security.